Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:IKT NASDAQ:IZTC NYSE:PLX NYSE:RCOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$1.56-7.1%$1.76$1.12▼$4.20$116.25M0.92183,507 shs78,545 shsIZTCInvizyne Technologies$12.40$10.02$8.50▼$23.00$103.16MN/A37,647 shs1,129 shsPLXProtalix BioTherapeutics$1.81+4.0%$1.54$0.99▼$3.10$144.32M-0.23827,114 shs908,440 shsRCORRenovacor$3.20$3.07$1.34▼$9.74$55.26M-0.2830,033 shsN/AThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics0.00%-6.59%-8.77%-16.13%+18.18%IZTCInvizyne Technologies+5.44%+3.68%+24.12%-3.20%+1,239,999,900.00%PLXProtalix BioTherapeutics0.00%+17.53%+19.08%+21.48%+74.04%RCORRenovacor0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$1.56-7.1%$1.76$1.12▼$4.20$116.25M0.92183,507 shs78,545 shsIZTCInvizyne Technologies$12.40$10.02$8.50▼$23.00$103.16MN/A37,647 shs1,129 shsPLXProtalix BioTherapeutics$1.81+4.0%$1.54$0.99▼$3.10$144.32M-0.23827,114 shs908,440 shsRCORRenovacor$3.20$3.07$1.34▼$9.74$55.26M-0.2830,033 shsN/AThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics0.00%-6.59%-8.77%-16.13%+18.18%IZTCInvizyne Technologies+5.44%+3.68%+24.12%-3.20%+1,239,999,900.00%PLXProtalix BioTherapeutics0.00%+17.53%+19.08%+21.48%+74.04%RCORRenovacor0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIKTInhibikase Therapeutics 2.50Moderate Buy$6.50316.67% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/APLXProtalix BioTherapeutics 3.00Buy$15.00728.73% UpsideRCORRenovacor 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/APLXProtalix BioTherapeutics$61.95M2.33$0.10 per share17.80$0.47 per share3.85RCORRenovacorN/AN/AN/AN/A$2.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/AIZTCInvizyne TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/APLXProtalix BioTherapeutics$8.31M$0.07N/A5.84N/A-21.03%-30.89%-11.74%N/ARCORRenovacor-$14.10M-$0.73N/AN/AN/AN/A-62.88%-48.90%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIKTInhibikase TherapeuticsN/A0.850.85IZTCInvizyne TechnologiesN/AN/AN/APLXProtalix BioTherapeuticsN/A1.981.27RCORRenovacorN/A6.606.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIKTInhibikase Therapeutics3.81%IZTCInvizyne TechnologiesN/APLXProtalix BioTherapeutics16.53%RCORRenovacor45.84%Insider OwnershipCompanyInsider OwnershipIKTInhibikase Therapeutics7.30%IZTCInvizyne TechnologiesN/APLXProtalix BioTherapeutics6.50%RCORRenovacor14.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIKTInhibikase Therapeutics674.52 million66.18 millionNot OptionableIZTCInvizyne Technologies296.25 millionN/AN/APLXProtalix BioTherapeutics20079.73 million69.00 millionOptionableRCORRenovacor1917.27 million14.78 millionNot OptionableRCOR, PLX, IKT, and IZTC HeadlinesRecent News About These CompaniesRenovacor, Inc. Common Stock (RCOR)June 12, 2025 | nasdaq.comBest budget record players 2024: affordable turntables tried and testedNovember 6, 2024 | whathifi.comWThe Lititz Record-ExpressOctober 25, 2024 | lancasteronline.comLWNBA Delivers Record-Setting 2024 SeasonOctober 13, 2024 | wnba.comWRBC Core Bond Pool ETF (RCOR)July 27, 2024 | investing.comRecord Store Day 2024: How to Flatten Warped Vinyl Records at HomeApril 22, 2024 | cnet.comThe best record players 2024: Top turntables for any budgetApril 20, 2024 | tomsguide.comTBest turntables 2024: Bluetooth record players for Record Store DayApril 20, 2024 | stuff.tvSNews of RecordMarch 30, 2024 | newsandsentinel.comNNHL opening night delivers record viewership on ESPNNovember 6, 2023 | nhl.comNState Pension payments worth over £2,000 each month for older people living in these European countriesOctober 30, 2023 | dailyrecord.co.ukDThe best early Black Friday turntable deals 2023October 28, 2023 | whathifi.comWAnas Sarwar 'unhappy' with Keir Starmer over Labour leader's response to Gaza crisisOctober 27, 2023 | dailyrecord.co.ukDNYC shoplifting hit record highs last year: ‘We can’t stop them’October 24, 2023 | nypost.comNTranscriptional control of the inflammatory responseOctober 18, 2023 | nature.comNRockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of DirectorsOctober 17, 2023 | finance.yahoo.comFolwell criticizes fellow Republicans on public records rollbackOctober 14, 2023 | wral.comWBest Bluetooth turntables 2023: wireless record players for streaming vinylOctober 11, 2023 | whathifi.comWHere’s why you shouldn’t record meltdowns on an airplane: FAA insiderOctober 3, 2023 | nypost.comNRecord-breaking heat wave peaking in Eastern U.S. with highs near 100September 28, 2023 | washingtonpost.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRCOR, PLX, IKT, and IZTC Company DescriptionsInhibikase Therapeutics NYSE:IKT$1.56 -0.12 (-7.14%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.57 +0.01 (+0.71%) As of 09/12/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Invizyne Technologies NASDAQ:IZTC$12.40 0.00 (0.00%) As of 09/12/2025Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.Protalix BioTherapeutics NYSE:PLX$1.81 +0.07 (+4.02%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.81 0.00 (0.00%) As of 09/12/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Renovacor NYSE:RCORRenovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
